Jian Qiang Li
Founder at Hebei Senlangbio Biotechnology Co., Ltd.
Profile
Jian Qiang Li is the founder and holds the title of Director & Chief Scientific Officer at Hebei Senlangbio Biotechnology Co., Ltd., which was founded in 2016.
Dr. Li obtained a doctorate degree from Julius-Maximilians-Universität Würzburg in 2009 and a graduate degree from Peking Union Medical College in 2006.
Jian Qiang Li active positions
Companies | Position | Start |
---|---|---|
Hebei Senlangbio Biotechnology Co., Ltd.
Hebei Senlangbio Biotechnology Co., Ltd. BiotechnologyHealth Technology Hebei Senlangbio Biotechnology Co., Ltd. is a clinical-stage biotechnology company based in Shijiazhuang, China. The Chinese company is dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers. Senlangbio has three cell therapy technology platforms, including chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR gamma delta T-cells (CAR-GDT), and armored tumor infiltrating lymphocytes (armTILs). Senlangbio is currently the largest cell therapy company in terms of the scale of bio-manufacturing, as well as the breadth and depth of active pre-clinical research and clinical development programs. The private company is in the process of further capturing the cell therapy markets in other regions and planning for international multi-center clinical studies. The company was founded in 2016 by Jian Qiang Li. | Founder | 27/01/2016 |
Training of Jian Qiang Li
Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Peking Union Medical College | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Hebei Senlangbio Biotechnology Co., Ltd.
Hebei Senlangbio Biotechnology Co., Ltd. BiotechnologyHealth Technology Hebei Senlangbio Biotechnology Co., Ltd. is a clinical-stage biotechnology company based in Shijiazhuang, China. The Chinese company is dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers. Senlangbio has three cell therapy technology platforms, including chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR gamma delta T-cells (CAR-GDT), and armored tumor infiltrating lymphocytes (armTILs). Senlangbio is currently the largest cell therapy company in terms of the scale of bio-manufacturing, as well as the breadth and depth of active pre-clinical research and clinical development programs. The private company is in the process of further capturing the cell therapy markets in other regions and planning for international multi-center clinical studies. The company was founded in 2016 by Jian Qiang Li. | Health Technology |
- Stock Market
- Insiders
- Jian Qiang Li